company background image
2INV

2invest XTRA:2INV Stock Report

Last Price

€11.30

Market Cap

€65.0m

7D

0%

1Y

-9.6%

Updated

20 May, 2022

Data

Company Financials +
2INV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

2INV Stock Overview

2invest AG, an investment company, acquires, holds, manages, and sells investments in corporations and partnerships primarily in the biotechnology, life science, and IT sectors in Germany and internationally.

2invest Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for 2invest
Historical stock prices
Current Share Price€11.30
52 Week High€13.46
52 Week Low€10.40
Beta0.52
1 Month Change2.73%
3 Month Change-11.02%
1 Year Change-9.60%
3 Year Change36.77%
5 Year Change-30.17%
Change since IPO-67.41%

Recent News & Updates

Shareholder Returns

2INVDE BiotechsDE Market
7D0%4.3%-0.1%
1Y-9.6%-31.4%-12.9%

Return vs Industry: 2INV exceeded the German Biotechs industry which returned -31.6% over the past year.

Return vs Market: 2INV exceeded the German Market which returned -13.3% over the past year.

Price Volatility

Is 2INV's price volatile compared to industry and market?
2INV volatility
2INV Average Weekly Movement3.1%
Biotechs Industry Average Movement8.2%
Market Average Movement6.3%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market3.5%

Stable Share Price: 2INV is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 2INV's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a3n/ahttps://2invest-ag.com

2invest AG, an investment company, acquires, holds, manages, and sells investments in corporations and partnerships primarily in the biotechnology, life science, and IT sectors in Germany and internationally. The company was formerly known as 4basebio AG and changed its name to 2invest AG in January 2021. 2invest AG is based in Heidelberg, Germany.

2invest Fundamentals Summary

How do 2invest's earnings and revenue compare to its market cap?
2INV fundamental statistics
Market Cap€64.95m
Earnings (TTM)-€1.89m
Revenue (TTM)€1.99m

32.6x

P/S Ratio

-34.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2INV income statement (TTM)
Revenue€1.99m
Cost of Revenue€0
Gross Profit€1.99m
Other Expenses€3.88m
Earnings-€1.89m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin100.00%
Net Profit Margin-94.83%
Debt/Equity Ratio5.1%

How did 2INV perform over the long term?

See historical performance and comparison

Valuation

Is 2invest undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.79x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2INV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2INV's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 2INV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: 2INV is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2INV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2INV is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (1.5x).


Future Growth

How is 2invest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


78.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2INV's forecast earnings growth is above the savings rate (-0.05%).

Earnings vs Market: Insufficient data to determine if 2INV's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2INV's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 2INV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2INV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has 2invest performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


36.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2INV is currently unprofitable.

Growing Profit Margin: 2INV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2INV is unprofitable, but has reduced losses over the past 5 years at a rate of 36.3% per year.

Accelerating Growth: Unable to compare 2INV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2INV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: 2INV has a negative Return on Equity (-2.29%), as it is currently unprofitable.


Financial Health

How is 2invest's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 2INV's short term assets (€71.8M) exceed its short term liabilities (€4.5M).

Long Term Liabilities: 2INV's short term assets (€71.8M) exceed its long term liabilities (€266.0K).


Debt to Equity History and Analysis

Debt Level: 2INV has more cash than its total debt.

Reducing Debt: 2INV's debt to equity ratio has reduced from 8.6% to 5.1% over the past 5 years.

Debt Coverage: 2INV's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 2INV earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is 2invest current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2INV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2INV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2INV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2INV's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2INV has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

2invest has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 2INV's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: 2INV's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

2invest AG's employee growth, exchange listings and data sources


Key Information

  • Name: 2invest AG
  • Ticker: 2INV
  • Exchange: XTRA
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €64.954m
  • Shares outstanding: 5.75m
  • Website: https://2invest-ag.com

Number of Employees


Location

  • 2invest AG
  • Ziegelhäuser Landstr. 3
  • Heidelberg
  • Baden-Württemberg
  • 69120
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/20 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.